Read More: It’s not simple shyness, it’s agoraphobia: the fear that quietly keeps you home may show up in signs you never linked to anxiety<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThat damage can turn ordinary things, such as climbing stairs or getting out of a car, into a painful calculation. Current care<\/a> includes exercise<\/a>, weight management, pain relievers, anti-inflammatory drugs, and injections, while advanced disease may require joint replacement.<\/p>\n\n\n\nThose options can reduce symptoms and restore mobility, but they do not reliably rebuild the original smooth cartilage. Researchers are still looking for an approved medicine that can slow, stop, or reverse the structural damage, which is why this result has drawn attention.<\/p>\n\n\n\n
The aging enzyme behind the result<\/h2>\n\n\n\n
The target is 15-PGDH<\/a>, an enzyme that becomes more abundant in several tissues with age. The researchers call it a \u201cgerozyme,\u201d meaning an aging-linked enzyme that helps drive the gradual loss of tissue function.<\/p>\n\n\n\nIn old mouse knee cartilage, 15-PGDH levels were about twice those found in young animals. The enzyme breaks down prostaglandin E2, a natural chemical signal involved in repair, so blocking it leaves more of that signal available.<\/p>\n\n\n\n
The idea has a longer history. Research published in 2015<\/a> showed that inhibiting 15-PGDH boosted regeneration in several mouse tissues, giving scientists a reason to test whether the same pathway could help stubborn joint cartilage.<\/p>\n\n\n\nCartilage cells reset without stem cells<\/h2>\n\n\n\n
The work came from Stanford Medicine, with contributions from Sanford Burnham Prebys Medical Discovery Institute, and was led by Mamta Singla and Yu Xin Wang. Senior author Nidhi Bhutani<\/a> said, \u201cCartilage regeneration to such an extent in aged mice took us by surprise.\u201d<\/p>\n\n\n\n\n\n\nRead More: Immanuel Kant, German philosopher: “You are not free when you break every rule but when you choose to obey reason within yourself”<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nResearchers gave old mice a small-molecule inhibitor either throughout the body or directly into the knee. In both cases, thinned cartilage became thicker across the joint surface, and tests identified it as functional hyaline cartilage, the smooth type joints need, rather than the tougher, less flexible repair tissue known as fibrocartilage.<\/p>\n\n\n\n
The repair did not depend on stem cells. Existing cartilage cells changed which genes they used and shifted toward a younger pattern, while the share linked with healthy articular cartilage rose from about 22% to 42%.
Helen Blau<\/a>, the other senior author and director of the Baxter Laboratory for Stem Cell Biology, said, \u201cWe were looking for stem cells, but they are clearly not involved.\u201d<\/p>\n\n\n\n![\"Doctor](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/07\/knee-cartilage-regeneration-osteoarthritis-aging-protein-study.jpg\" "\\"\\"")
A knee joint model illustrates the cartilage affected by osteoarthritis, the focus of new research exploring regeneration by blocking an aging-linked protein.<\/figcaption><\/figure>\n\n\n\nInjury and human tissue tests<\/h2>\n\n\n\n
The team also created a knee injury in mice similar to an anterior cruciate ligament tear. Inhibitor injections<\/a> given twice a week for four weeks sharply reduced later joint damage, and treated animals moved more normally and placed more weight on the injured leg. <\/p>\n\n\n\nAbout half of people with this common sports injury develop osteoarthritis in the affected joint within roughly 15 years.<\/p>\n\n\n\n
The human test used cartilage from 11 patients ages 55 to 75 who were undergoing total knee replacement. After one week outside the body, treated samples showed fewer destructive cartilage cells, less activity from inflammation and breakdown genes, and early production of new articular cartilage.<\/p>\n\n\n\n
Still, tissue in a laboratory dish cannot reveal whether a person would feel less pain, walk farther, avoid side effects, or keep the new cartilage for years. That is the line future clinical trials must cross.<\/p>\n\n\n\n
Why joint replacement is not over<\/h2>\n\n\n\n
No human cartilage trial has yet reported that this approach repairs an arthritic knee or hip. Mouse joints carry weight differently, and researchers must determine the right dose, treatment length, delivery method, and long-term effects of changing prostaglandin signaling.<\/p>\n\n\n\n
An oral inhibitor of the same target called MF-300, developed by Epirium Bio, completed Phase 1 testing in 100 healthy adults. <\/p>\n\n\n\n
\n\n\nRead More: New research reveals a hidden link between Parkinson’s and dementia that could change how you spot the earliest warning signs<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThe company\u2019s Phase 1 results<\/a> reported no serious adverse events after single doses or five days of daily dosing, and the developer now lists the drug in a Phase 2b study<\/a> for age-related muscle weakness. That is useful safety information, but it is not proof of cartilage repair.<\/p>\n\n\n\nHuman osteoarthritis studies will need to measure pain, movement, imaging changes, durability, and whether treatment can truly delay or prevent surgery. The official release also disclosed related patent applications, a license to the drug developer, and a financial interest held by one senior author. <\/p>\n\n\n\n
For now, joint replacement<\/a> remains a well-established option for end-stage disease, while this enzyme blocker remains a promising but unproven regenerative strategy.<\/p>\n\n\n\nThe official study has been published in <\/a>Science<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Could a worn-out knee repair its own smooth lining instead of being replaced with metal and plastic? A new preclinical … <\/p>\n
Those options can reduce symptoms and restore mobility, but they do not reliably rebuild the original smooth cartilage. Researchers are still looking for an approved medicine that can slow, stop, or reverse the structural damage, which is why this result has drawn attention.<\/p>\n\n\n\n
The aging enzyme behind the result<\/h2>\n\n\n\n
The target is 15-PGDH<\/a>, an enzyme that becomes more abundant in several tissues with age. The researchers call it a \u201cgerozyme,\u201d meaning an aging-linked enzyme that helps drive the gradual loss of tissue function.<\/p>\n\n\n\n In old mouse knee cartilage, 15-PGDH levels were about twice those found in young animals. The enzyme breaks down prostaglandin E2, a natural chemical signal involved in repair, so blocking it leaves more of that signal available.<\/p>\n\n\n\n The idea has a longer history. Research published in 2015<\/a> showed that inhibiting 15-PGDH boosted regeneration in several mouse tissues, giving scientists a reason to test whether the same pathway could help stubborn joint cartilage.<\/p>\n\n\n\n The work came from Stanford Medicine, with contributions from Sanford Burnham Prebys Medical Discovery Institute, and was led by Mamta Singla and Yu Xin Wang. Senior author Nidhi Bhutani<\/a> said, \u201cCartilage regeneration to such an extent in aged mice took us by surprise.\u201d<\/p>\n\n\n\n Researchers gave old mice a small-molecule inhibitor either throughout the body or directly into the knee. In both cases, thinned cartilage became thicker across the joint surface, and tests identified it as functional hyaline cartilage, the smooth type joints need, rather than the tougher, less flexible repair tissue known as fibrocartilage.<\/p>\n\n\n\n The repair did not depend on stem cells. Existing cartilage cells changed which genes they used and shifted toward a younger pattern, while the share linked with healthy articular cartilage rose from about 22% to 42%. The team also created a knee injury in mice similar to an anterior cruciate ligament tear. Inhibitor injections<\/a> given twice a week for four weeks sharply reduced later joint damage, and treated animals moved more normally and placed more weight on the injured leg. <\/p>\n\n\n\n About half of people with this common sports injury develop osteoarthritis in the affected joint within roughly 15 years.<\/p>\n\n\n\n The human test used cartilage from 11 patients ages 55 to 75 who were undergoing total knee replacement. After one week outside the body, treated samples showed fewer destructive cartilage cells, less activity from inflammation and breakdown genes, and early production of new articular cartilage.<\/p>\n\n\n\n Still, tissue in a laboratory dish cannot reveal whether a person would feel less pain, walk farther, avoid side effects, or keep the new cartilage for years. That is the line future clinical trials must cross.<\/p>\n\n\n\n No human cartilage trial has yet reported that this approach repairs an arthritic knee or hip. Mouse joints carry weight differently, and researchers must determine the right dose, treatment length, delivery method, and long-term effects of changing prostaglandin signaling.<\/p>\n\n\n\n An oral inhibitor of the same target called MF-300, developed by Epirium Bio, completed Phase 1 testing in 100 healthy adults. <\/p>\n\n\n\n The company\u2019s Phase 1 results<\/a> reported no serious adverse events after single doses or five days of daily dosing, and the developer now lists the drug in a Phase 2b study<\/a> for age-related muscle weakness. That is useful safety information, but it is not proof of cartilage repair.<\/p>\n\n\n\n Human osteoarthritis studies will need to measure pain, movement, imaging changes, durability, and whether treatment can truly delay or prevent surgery. The official release also disclosed related patent applications, a license to the drug developer, and a financial interest held by one senior author. <\/p>\n\n\n\n For now, joint replacement<\/a> remains a well-established option for end-stage disease, while this enzyme blocker remains a promising but unproven regenerative strategy.<\/p>\n\n\n\n The official study has been published in <\/a>Science<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Could a worn-out knee repair its own smooth lining instead of being replaced with metal and plastic? A new preclinical … <\/p>\nCartilage cells reset without stem cells<\/h2>\n\n\n\n
Read More: Immanuel Kant, German philosopher: “You are not free when you break every rule but when you choose to obey reason within yourself”<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Helen Blau<\/a>, the other senior author and director of the Baxter Laboratory for Stem Cell Biology, said, \u201cWe were looking for stem cells, but they are clearly not involved.\u201d<\/p>\n\n\n\n
A knee joint model illustrates the cartilage affected by osteoarthritis, the focus of new research exploring regeneration by blocking an aging-linked protein.<\/figcaption><\/figure>\n\n\n\nInjury and human tissue tests<\/h2>\n\n\n\n
Why joint replacement is not over<\/h2>\n\n\n\n
Read More: New research reveals a hidden link between Parkinson’s and dementia that could change how you spot the earliest warning signs<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n